Search Results
Your search for ,ASh matches 1521 pages
Showing 1301 - 1350Idelalisib Achieves High Response Rates in ‘Double-Refractory’ Indolent NHL
In patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to both rituximab (Rituxan) and an alkylating agent, monotherapy with the selective oral PI3K-delta inhibitor idelalisib produced a high response rate, with responses persisting for 1 year in the average patient, according to...
Expert Point of View: Jennifer R. Brown, MD, PhD
Idelalisib is being studied in three ongoing registration trials. [Study 116] was stopped early after idelalisib/rituximab demonstrated high efficacy in relapsed chronic lymphocytic leukemia [CLL],” said Jennifer R. Brown, MD, PhD, Director of the CLL Center at Dana-Farber Cancer Institute, Boston. ...
Idelalisib Plus Rituximab in Heavily Pretreated Relapsed CLL: ‘Dawn of a New Age’?
Idelalisib plus rituximab (Rituxan) improved progression-free survival, overall response rates, and overall survival compared with rituximab alone in heavily pretreated patients with relapsed chronic lymphocytic leukemia (CLL). Moreover, the combination provided effective, durable disease control...
Promising Results Demonstrated for Brentuximab Vedotin in Cutaneous T-Cell Lymphoma
Phase II results suggest that brentuximab vedotin (Adcetris) has encouraging activity in CD30-positive cutaneous T-cell lymphomas and lymphoproliferative disorders, including mycosis fungoides, the most common type of cutaneous T-cell lymphoma. High levels of responses were achieved in a 48-patient ...
Novel Therapies May Help Wipe Out Residual Acute Lymphoblastic Leukemia
Minimal residual disease after induction and consolidation for the treatment of acute leukemia might be eradicated by novel therapies, thus obviating the need for stem cell transplantation. That is the prediction of Matthew J. Wieduwilt, MD, PhD, Assistant Clinical Professor of Medicine at the...
Minimal Residual Disease Before and After Transplant: What Does It Mean?
In patients with acute leukemia, outcomes after hematopoietic stem cell transplantation are negatively impacted by the presence of minimal residual disease. However, transplant can prolong survival in patients with minimal residual disease after consolidation, according to two studies presented at...
2014 Oncology Meetings
APRIL 15th Annual Meeting of the American Society of Breast SurgeonsApril 30-May 4 • Las Vegas, NevadaFor more information:www.breastsurgeons.org/index.php MAY Oncology Nursing Society 39th Annual CongressMay 1-4 • Anaheim, CaliforniaFor more information: www.ons.org Association for Value-Based...
Unraveling the Molecular Complexity of Multiple Myeloma
In 2011, the Multiple Myeloma Research Foundation (MMRF) announced the launch of CoMMpass (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile), a clinical study at the heart of its Personalized Medicine Initiative. CoMMpass will follow 1,000 newly diagnosed...
‘Double-Hit’ Lymphomas a Challenge for the Oncologist
"Double-hit” lymphomas remain challenging tumors, and the best means of treatment remains somewhat elusive, according to studies presented at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans, and experts who commented on these findings. “We still don’t have a standard of...
ASH Awards Bridge Grants to 15 Investigators
The American Society of Hematology (ASH) recently announced the names of 15 researchers (see sidebar on page 15) who will receive interim support from the Society for hematology research proposals. These proposals earned high scores but could not be funded by the National Institutes of Health (NIH) ...
Better Options Emerging for Salvage Therapy in Hodgkin Lymphoma
Emerging effective treatment options for salvage therapy in Hodgkin lymphoma were described by Anas Younes, MD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, New York, at the 2014 Highlights of ASH in North America meeting in Miami. “This is an exciting time in Hodgkin...
2014 Oncology Meetings
MAY Association for Value-Based Cancer Care – 4th Annual ConferenceMay 6-9 • Los Angeles, CaliforniaFor more information: http://avbcconline.org/ Accelerating Anticancer Agent Development and Validation WorkshopMay 7-9 • Bethesda, MarylandFor more information: www.acceleratingworkshop.org/ Current...
Promising Compounds in Development for Multiple Myeloma
The term “novel agents” has been used for the past decade to describe proteasome inhibitors and immunomodulatory drugs that are now conventionally used for multiple myeloma. However, even newer agents in development will be considered truly novel when they hit the market, as they represent new...
SIDEBAR: Statement From ASH President Linda J. Burns, MD, on Release of Medicare Physician Payment Data
The Centers for Medicare & Medicaid Services has released a large and complex set of data about the number and type of health-care services that individual physicians and certain other health-care professionals delivered in 2012, and the amount Medicare paid them for those services. The data,...
Maintenance Therapy in Multiple Myeloma
In 2012, three randomized placebo-controlled trials reported a significant prolongation of progression-free survival with lenalidomide (Revlimid) as maintenance therapy for multiple myeloma.1-3 Two of these trials tested lenalidomide maintenance after stem cell transplantation, and one investigated ...
2014 Oncology Meetings
MAY ASPHO’s 27th Annual MeetingMay 14-17 • Chicago, Illinois For more information: www.aspho.org Oral Oncology: Oncologic Dentistry and Maxillofacial Prosthetics SymposiumMay 15-17 • Houston, TexasFor more information: www.mdanderson.org/conferences 2014 State of the Art Radiation Therapy:...
Forward Progress in Myelodysplastic Syndromes Is Largely in Genetics
Most recent advances in the management of myelodysplastic syndrome (MDS) are in the area of genetics, according to Steven Gore, MD, of Yale University School of Medicine, New Haven. “New genomics research is leading to a better understanding of MDS heterogeneity and disease biology, and may...
Challenges in Creating and Promoting Clinical Practice Guidelines
With regard to clinical practice guidelines, clinicians want an authoritative resource that will clearly and concisely instruct them in most clinical scenarios. Guideline developers want to give them this, “but producing guidelines is not as straightforward as it might seem,” according to David...
Enthusiasm and Vision Guide the Head of FDA’s Oncology Office
In 2005, Richard Pazdur, MD, was named the FDA’s Director of the Office of Hematology and Oncology Products. By any measure, being arbiter of the nation’s oncology drug pipeline is a daunting prospect, but Dr. Pazdur sees it as an opportunity to encourage his talented staff to work for the greater ...
2014 Oncology Meetings
JUNE National Coalition of Oncology Nurse Navigators 5th Annual Conference: Setting the Course for Improved Cancer CareJune 12-14 • Atlanta, Georgia For more information: www.nconnconference.com Targeting VEGF-mediated Tumor Angiogenesis in Cancer TherapyJune 19-20 • New York, New York For more...
Unprecedented Release of Medicare Data Raises Concerns About Lack of Context: Statements From COA and ASTRO
In April, as part of the Obama administration’s work to make the U.S. health-care system more transparent, affordable, and accountable, the Centers for Medicare & Medicaid Services (CMS) released a vast amount of privacy-protected data on services and procedures provided to Medicare...
2014 Oncology Meetings
JUNE MASCC/ISOO International Symposium on Supportive Care in CancerJune 26-28 • Miami, Florida For more information: www.mascc.org/symposium European Conference of Oncology Pharmacy 2June 26-28 • Krakow, Poland For more information: http://ecop2014.wordpress.com 6th International Workshop on...
2014 Oncology Meetings
JULY Breast Cancer: New Horizons, Current ControversiesJuly 10-12 • Boston, Massachusetts For more information: www.hms-cme.net/341279/ The 12th Annual Scientific Meeting of Japanese Society of Medical OncologyJuly 17-19 • Fukuoka, Japan For more information: www.congre.co.jp/jsmo2014/en/ The 13th...
2014 Oncology Meetings
JULY 5th World Congress of International Federation of Head and Neck Oncologic Societies Annual Meeting of American Head and Neck SocietyJuly 26-30 • New York, New YorkFor more information:www.ahns.info/meetings/index.php AACR/ASCO Methods in Clinical Cancer Research WorkshopJuly 26-August 1 •...
2014 Oncology Meetings
AUGUST Best of ASCO® ChicagoAugust 15-16 • Chicago, Illinois For more information: boa.asco.org 16th Annual Scientific Meeting: AGITG Trials in ActionAugust 20-22 • Brisbane, Australia For more information: www.agitg.asnevents.com.au 29th International Papillomavirus Conference and Clinical &...
2014 Oncology Meetings
SEPTEMBER American Society for Radiation Oncology Annual MeetingSeptember 14-17 • San Francisco, California For more information: www.astro.org Cancer Medicine and Hematology 2014September 14-19 • Boston, Massachusetts For more information: www.hmscme.com/cancermedicine 18th Annual Meeting:...
Treating Multiple Myeloma in 2014
The field of multiple myeloma is rapidly changing, and the shifts that are occurring impact the management of these patients, from initial diagnosis through multiple relapses. At the 9th Annual New Orleans Summer Cancer Meeting, Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant...
Jury Still Out on Interim PET for Response-Adapted Therapy in Hodgkin Lymphoma
Interim positron-emission tomography (PET) scans provide good prognostic information in patients with Hodgkin lymphoma, but more research is needed to determine whether patients benefit when the findings are used to alter treatment, according to Oliver Press, MD, PhD, Professor at the University of ...
2014 Oncology Meetings
SEPTEMBER Celebrating 100 Years of Retinoblastoma Center in New York: 1914-2014September 18-19 • New York, New York For more information: www.mskcc.org/events/cme Palliative Medicine and Supportive Oncology 2014 – The 17th International SymposiumSeptember 18-20 • Henderson, Nevada For more...
2014 Oncology Meetings
OCTOBER 18th SIS World Congress on Breast HealthcareOctober 16-19 • Orlando, Florida For more information: www2.kenes.com/sis/Pages/Home.aspx 2014 Quality Care SymposiumOctober 17-18 • Boston, MassachusettsFor more information: quality.asco.org Atlanta Lung Cancer SymposiumOctober 18 • Atlanta,...
Ketan K. Badani, MD, Additional Staff, Appointed to Mount Sinai Health System
Ketan K. Badani, MD, Professor of Urology, Icahn School of Medicine at Mount Sinai in New York, has been named Vice Chairman of Urology and Robotic Operations and Director of the Comprehensive Kidney Cancer Program for the Mount Sinai Health System. Dr. Badani will also serve as Director of Robotic ...
Statement from ASH President Linda J. Burns, MD, on Release of Sunshine Act Data
The Centers for Medicare & Medicaid Services (CMS) has released a large set of data about the payments physicians and teaching hospitals received from pharmaceutical and medical device companies from August 1 to December 31, 2013. This public disclosure, mandated under a provision of the...
2014 Oncology Meetings
NOVEMBER Chemotherapy Foundation SymposiumNovember 4 - 8 • New York, New YorkFor more information:www.chemotherapyfoundationsymp-osium.org Diagnostic Error in Medicine 5th International ConferenceNovember 11-14 • Baltimore, MarylandFor more information:www.hopkinscme.edu/CourseDetail.aspx/80028747...
Experts Debate the Need for Upfront vs Late Stem Cell Transplant in Multiple Myeloma
With powerful new drugs capable of achieving sustained and deep remissions in multiple myeloma, the role of upfront stem cell transplantation is being questioned by experts, who debated the pros and cons at the National Comprehensive Cancer Network (NCCN) 9th Annual Congress on Hematologic...
2014 Oncology Meetings
NOVEMBER EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer TherapeuticsNovember 18-21 • Barcelona, SpainFor more information: www.aacr.org ESMO Symposium on Immuno-OncologyNovember 21-22 • Geneva, Switzerland For more information: www.esmo.org/Conferences/Immuno-Oncology-2014...
2014 Oncology Meetings
DECEMBER Society of Urologic Oncology 15th Annual MeetingDecember 3-5 • Bethesda, Maryland For more information: http://suonet.org/meetings/2014/default.aspx UICC World Cancer CongressDecember 3-6 • Melbourne, AustraliaFor more information: www.worldcancercongress.org 1st Rome International Meeting ...
ASH Awards New Bridge Grants to Help Alleviate Pain of Federal Funding Cuts
In November, the American Society of Hematology (ASH) announced the names of seven recipients of its Bridge Grant awards. These 1-year, $150,000 awards provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the National...
The American Society of Hematology Elects New Leadership
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee, the governing body of the organization, for terms beginning after the 2014 ASH Annual Meeting, which will be held December 6–9 in San Francisco. Kenneth C. Anderson, MD, will...
ASH Pairs Hematologists From Developing and Developed Nations for Global Training Program
The American Society of Hematology (ASH) recently announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity ...
New Agents and Novel Targets for Multiple Myeloma
New therapies for multiple myeloma have dramatically improved life expectancy, but despite these advances, 5-year overall survival still remains below 50%. Investigators are in hot pursuit of new therapies that will extend remissions and improve survival. Thus far, monoclonal antibodies,...
ASH Honors Senator Barbara Mikulski and Patient Advocate Kathy Giusti
The American Society of Hematology (ASH) recognized Senator Barbara Mikulski (D-MD) and Kathy Giusti, Founder of the Multiple Myeloma Research Foundation, with awards for their outstanding support and advocacy for biomedical research and the practice of hematology at the 56th ASH Annual Meeting in...
Top 10 Articles From The ASCO Post in 2014
The following list presents those articles published in 2014 that were observed most often by visitors to ASCOPost.com, as measured by the number of views.a To view the full version of the articles listed below, visit ASCOPost.com and enter the URL provided below each entry. 1. Continuous...
ASH Releases Second List for Choosing Wisely Campaign
The American Society of Hematology (ASH) has announced five additional commonly used tests, treatments, and procedures in hematology that physicians and patients should question in certain circumstances. The additional items join an initial list of five practices to question that the Society...
PD-1 Blockade Moves Into Hematology
The promise of the programmed death receptor-1 (PD-1) inhibitors seen in solid tumors, especially melanoma, may hold true for at least one hematologic malignancy, according to studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. At a press briefing, data ...
Panelists Lambast, Explore the High Cost of Cancer Drugs
At the 2014 American Society of Hematology Annual Meeting, a symposium on the high cost of cancer drugs proved provocative and a bit testy as panelists presented their various points of view. ‘Medical Darwinian System’ Already known for his outspoken views on the topic is Hagop M. Kantarjian, MD,...
Will Checkpoint Inhibitors Be Winners in Hematologic Cancers, Too?
A “Featured Topic” session during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition drew a standing-room-only crowd to hear two experts weigh in on checkpoint blockade in hematologic malignancies. While new to hematology, these drugs—the cytotoxic T-lymphocyte–associated...
Cleveland Clinic Piloting ‘Adaptive Therapy’ Approach in Multiple Myeloma
For newly diagnosed multiple myeloma patients, Cleveland Clinic specialists believe two drugs may suffice for most patients, bucking the trend toward using triplets for all patients and reserving them for patients with insufficient response to two. They described a pilot study of their “carepath”...
Victory for Pediatric Regimens in Adolescents and Young Adults With ALL
Long in the works, early results of the U.S. Intergroup C10403 trial clearly showed that treating acute lymphoblastic leukemia (ALL) in adolescents and young adults using a pediatric-inspired regimen improves event-free survival and overall survival and should be the backbone for future studies in...
Blinatumomab Achieves Complete Molecular Responses in Majority of B-Cell Leukemia Patients
Results from the international phase II BLAST study show that one cycle of blinatumomab (Blincyto) immunotherapy achieved complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.1 Complete minimal residual disease response was achieved in 80% of patients...
Venetoclax Gaining Ground in Two Types of Leukemia
Venetoclax, formerly known as ABT-199, is moving forward into phase III development in acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL), based on encouraging data from separate phase Ib and II trials presented at the 56th Annual Meeting and Exposition of the American Society...
